A Phase 3 Randomized Withdrawal, Double-blind, Placebo-controlled, Multi-center Study Investigating The Efficacy And Safety Of Pf-04965842 In Subjects Aged 12 Years And Over, With Moderate To Severe Atopic Dermatitis With The Option Of Rescue Treatment In Flaring Subjects
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms JADE-REGIMEN; REGIMEN
- Sponsors Pfizer
- 17 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 30 May 2019 Planned End Date changed from 3 Jul 2020 to 27 Aug 2020.
- 30 May 2019 Planned primary completion date changed from 3 Jul 2020 to 27 Aug 2020.